Novavax (NVAX) Given “Hold” Rating at Chardan Capital
A number of other research firms also recently issued reports on NVAX. B. Riley set a $10.00 target price on shares of Novavax and gave the company a buy rating in a research report on Thursday. Citigroup downgraded shares of Novavax from a buy rating to a neutral rating and set a $1.00 target price on the stock. in a research report on Tuesday, December 19th. S&P Equity Research lowered their price target on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. BidaskClub raised Novavax from a buy rating to a strong-buy rating in a research note on Wednesday, February 21st. Finally, Ladenburg Thalmann Financial Services reaffirmed a buy rating and issued a $3.50 price target on shares of Novavax in a research note on Thursday. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $3.11.
Novavax (NVAX) traded down $0.05 during trading on Thursday, reaching $2.09. 2,749,022 shares of the company’s stock were exchanged, compared to its average volume of 13,477,157. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31. Novavax has a 52 week low of $0.73 and a 52 week high of $2.75.
TRADEMARK VIOLATION NOTICE: “Novavax (NVAX) Given “Hold” Rating at Chardan Capital” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/novavax-nvax-given-hold-rating-at-chardan-capital/1909274.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.